H1N1: Slipping on a Slippery Disease

Posted by CSIS Staff on Oct 28, 2009 at 01:12 pm

Co-authored by Stephen Morrison and Phillip Nieburg, CSIS

The unusual clinical characteristics of the H1N1 virus and the uncertainties about H1N1 vaccine production have brought home powerfully the unpredictability -- the “slippery” nature -- of influenza virus and of the vaccines designed to reduce its disease burden. And it has revealed the complexities and risks in making numerical projections, amid great uncertainty, and communicating them effectively to the American people.

The President’s October 23rd Declaration of a National Emergency because of the H1N1 epidemic has raised both anxieties and additional questions about H1N1 influenza and about the H1N1 vaccine intended to protect us.

A formal declaration of a National Emergency provides Department of Health and Human Services Secretary Sebelius with the legal authority to relax federal administrative requirements so that hospitals facing large – and potentially overwhelming - numbers of swine flu patients may use alternative facilities for treating such patients or could more easily transfer them to other, less overburdened, hospitals.

This anticipatory step is reasonable, given the real possibility of an enlarged crisis, although it would be preferable to handle as a strictly administrative measure, free of the drama and anxiety created by the President directly engaging to declare an emergency. It is worth reexamining the legal requirements for a purely administrative declaration along with the strategy to communicate that decision.

The drama of that National Emergency announcement and of the growing H1N1 death and severe illness toll has been compounded by the inability of many people, including those in high-risk categories, to gain access to the H1N1 vaccine that they had been told would be available by now. The announcement earlier this month of significant delays in production – and resulting shortfalls, however temporary - of H1N1 (swine) influenza vaccine were frustrating and alarming to those who had been convinced by effective public health messages and by individual providers to believe that the disease risk was severe enough that they should be immunized soon. Communications, public expectations, and production shortfalls were in collision, generating considerable confusion and anxiety.

The current situation has arisen as a result of several technical glitches in vaccine production combined with over-optimism among those responsible for projecting vaccine production and availability.

The major technical glitch in recent months is that the virus being used to produce the H1N1 vaccine has not been multiplying as quickly as expected in the chicken eggs used to incubate it. Since far less H1N1 virus than expected was becoming available to put into the vaccines, fewer vaccine doses could be produced.

Because the test material used to measure the amount of virus production has itself to be manufactured from scratch, using the same H1N1 flu virus stocks, it was only after that test material became available last month that the true magnitude of the shortfall became evident.

The United States has not experienced this level of public concern and uncertainty about influenza since 1976, when swine flu was last considered to be a major threat. Although influenza disease surveillance, anti-viral drugs and clinical care of ill people have all improved over the intervening 33 years, we still rely on an antiquated system of egg-based influenza vaccine production, with all of its uncertainties. A future policy priority should be accelerating technological improvements in vaccine production.

The Nexus of Faith and HealthThe contribution of faith-based organizations (FBOs) to health services and in reaching poor communities around the world has long been the subject of debate among public health experts and policymakers. To explore the nexus between faith and health, the CSIS Global Health Policy Center convened two recent events. The first focused on faith-based organizations and family planning in Kenya, and the

Polio Eradication: Nigeria Must Keep its Eye on the PrizeJuly 24 marks a significant milestone in the global effort to eradicate polio: Nigeria, one of the countries where wild poliovirus has proven hardest to extinguish, has reported no cases of the disease for a year. While the success should be celebrated, it also should be viewed with a note of caution.

A Real Test for the GFF: Improving Maternal and Child Health in Conflict SettingsA highlight of the Third International Conference on Financing for Development, held last week in Addis Ababa, Ethiopia, was the launch of a new Global Financing Facility (GFF) to end preventable maternal and child deaths by 2030. This partnership will bring together countries, UN agencies, multilateral groups, private sector investors, and civil society organizations in order to close the $33 bil

Successes in HIV Overshadow Failures in TBThe world is celebrating a giant milestone in the fight against HIV: 15 million people are now on lifesaving treatment using highly effective antiretroviral drugs! It’s a huge win for global health, and of course for the millions whose lives have been saved.

Obama’s Kenya Trip Should Elevate Focus on Women and GirlsThe President could cement a lasting legacy by explicitly linking U.S. Africa policy to the health and empowerment of women and girls, arguably the continent’s most dynamic and underdeveloped resource and an indispensable component of any successful economic and security program.